Skip to content
Screener

Amneal Pharmaceuticals, Inc. AMRX Total Non-Current Liabilities

Total Non-Current Liabilities at other companies

Harmony Biosciences Holdings, Inc. logo
Harmony Biosciences Holdings, Inc.HRMY
$144.14M-9.9%

Other financials

Income statement

See full
Revenue$796.2M+9.9%
Gross profit$334.5M+16.9%
Operating income$129.8M+16.5%
Net income$57.7M+157%
EPS (diluted)$0.18+157%

Balance sheet

See full
Cash & equivalents$127.6M+78.4%
Total debt$2.6B+18.0%
Total equity$33.0M+129%
Total assets$3.8B+10.3%

Cash flow

See full
Operating cash flow-$21.2M-125%
CapEx$30.7M+34.5%
Free cash flow-$51.9M-185%

Valuation

See full
Market cap$5.77B+129%
Enterprise value$8.21B+77.4%
P/E36.7×-711×
P/S1.9×+1.0×

Profitability

See full
Gross margin39.3%+1.7pp
Operating margin14.6%+1.4pp
Net margin5%+4.9pp
FCF margin4.1%-5.8pp

Returns & leverage

See full
Return on equity-52.8%-12.7pp
Debt / equity77.8×
Current ratio2.2×+0.8×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesNoncurrent.

The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 5:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001723128-26-000031
Line itemJune 30, 2026December 31, 2025
Related party payables - long term2,89219,132
Liabilities for legal matters - long term70,83071,819
Other long-term liabilities32,11932,263
Total long-term liabilities2,776,1812,790,684
Commitments and contingencies (Notes 3, 16 and 18)
Redeemable non-controlling interests83,95677,292
Stockholders’ Equity (Deficiency)
Preferred stock, $0.01 par value, 2,000 shares authorized at both June 30, 2026 and December 31, 2025; none issued at both June 30, 2026 and December 31, 2025

Item 1. Financial Statements (Unaudited)

FAQ

What is Amneal Pharmaceuticals, Inc.'s total non-current liabilities?
Amneal Pharmaceuticals, Inc. (AMRX) reported total non-current liabilities of $2.78B in Q2 2026.
How has Amneal Pharmaceuticals, Inc.'s total non-current liabilities changed year-over-year?
Amneal Pharmaceuticals, Inc.'s total non-current liabilities increased by 17.5% year-over-year, from $2.36B to $2.78B.
What is the long-term trend for Amneal Pharmaceuticals, Inc.'s total non-current liabilities?
Over 5 years (2020 to 2025), Amneal Pharmaceuticals, Inc.'s total non-current liabilities has grown at a -1.3% compound annual growth rate (CAGR), from $2.97B to $2.79B.
What does total non-current liabilities mean?
The sum of all long-term obligations due beyond one year — long-term debt, lease liabilities, pension obligations, and deferred items.

Ask your AI about Amneal Pharmaceuticals, Inc.'s total non-current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude